SARS-CoV-2 Messenger RNA Vaccine Antibody Response and Reactogenicity in Heart and Lung Transplant Recipients: SARS-CoV-2 vaccine response in heart and lung recipients
Andrew M. Hallett(Johns Hopkins Medicine), Errol L. Bush(Johns Hopkins University), Allan B. Massie(Johns Hopkins University), Dorry L. Segev(New York University), Robert Higgins(Methodist Hospital), Julia I. López(Johns Hopkins Medicine), Michael T. Ou(Johns Hopkins University), William A. Werbel(Johns Hopkins University), Sunjae Bae(New York University), Jacqueline Garonzik‐Wang(University of Wisconsin–Madison), Michelle R. Krach(Johns Hopkins University), Ross S. Greenberg(Johns Hopkins University), Brian J. Boyarsky(Johns Hopkins University), Aura T. Teles(Johns Hopkins University), Pali D. Shah(Johns Hopkins University), Robin K. Avery(Johns Hopkins University)
The Journal of Heart and Lung Transplantation
January 1, 2021
Cited by 0
Related Papers
Foot strike patterns and collision forces in habitually barefoot versus shod runners
|Nature|2010|1.4k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
|JAMA|2021|1k
Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation
|American Journal of Respiratory and Critical Care Medicine|2013|686